|
|
Article: Cost and Financing of Care for Persons With HIV Disease: An Overview.
- Article from:
- Health Care Financing Review
- Article date:
- March 22, 1998
- Author:
CopyrightCOPYRIGHT 1998 U.S. Department of Health and Human Services. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
INTRODUCTION AND BACKGROUND
The recent approval of four protease inhibitors by the Food and Drug Administration initiated a new period in the treatment of persons with HIV disease. The first protease inhibitor, Invirase, was approved in December 1995. The second and third protease inhibitors (Crixivan and Norvir) were approved in March 1990, and the fourth protease inhibitor (Viracept) was approved in March 1997.
The rapid growth in the number of drugs approved to treat persons with HIV disease accompanied by improved techniques to monitor the quantity of virus in patients have transformed the treatment of persons with HIV disease. Today, there are 11 ...